Anifrolumab 

Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research^[1][2].

Anifrolumab (67.7 nM; 20 min) induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation^[2].
Anifrolumab (1 and 10 μg/mL; 6 or 7 d) suppresses differentiation of B cells into plasma cells^[2].
Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC₅₀s ranging from 0.004 to 0.3 nM for the IFN-α subtypes, and 0.03 nM and 0.07 nM for IFN-β and IFN-ω, respectively^[2].
Anifrolumab (67.7 nM) dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1326232-46-5

Liquid

Colorless to light yellow

[Anifrolumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Furie R, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386.  [Content Brief]

  [2]. Riggs JM, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018 Apr 5;5(1):e000261.  [Content Brief]